

[Code Number: 7979]

# Briefing Materials Financial Results and Forecasts for 3Q FY March 2024

February 2, 2024





# Consolidated Financial Results for 1-3Q FY March 2024

# Financial Forecasts for FY March 2024

TOPICS (Oct-Dec 2023)

# Highlights



#### Financial Results for 1-3Q FY March 2024

Net sales ¥25,403mn (Overseas sales ratio 57.4%)

Operating income ¥3,409mn

#### [YoY]

- Sales rose 7.0% following the launch of next-gen dental cameras, sales growth in existing products overseas, and forex effects
- > Operating income turned up YoY, rising 3.6% despite a sharp increase in SG&A due to upfront investments and efforts to bolster marketing, on the back of the sales growth.

#### [ FY March 2024 outlook]

#### Expecting record-high sales and profits for the third straight year

- The achievement rate (vs the revised plan on October 24, 2023) for sales and operating income is 72.8% and 79.1% respectively.
- Chemical product supply shortages and order backlogs were an ongoing issue since the previous fiscal year, but were largely resolved during 3Q. Efforts to improve profitability by capturing steady overseas demand were stepped up. We also focused on expanding sales in the domestic market of dental cutting resin materials and related products (newly covered by insurance), as well as self-care toothpaste (exclusively sold at dental offices), and other new products.

### Key earnings highlights for 1-3Q FY March 2024

SHOFU

Units: ¥mn, %

	1-3Q FY3/23 (% of sales)	1-3Q FY3/24 (% of sales)	Change From Previous Period (% change)	FY3/24 Forecast (% of sales)	
Net sales	<b>23,742</b> (100.0)	<b>25,403</b> (100.0)	<b>1,661</b> (7.0)	<b>34,888</b> ( 72.8)	
(Domestic sales)	<b>10,772</b> (45.4)	<b>10,812</b> (42.6)	<b>39</b> (0.4)	<b>14,851</b> ( 72.8)	
(Overseas sales)	<b>12,969</b> (54.6)	<b>14,590</b> (57.4)	<b>1,621</b> (12.5)	<b>20,037</b> ( 72.8)	
Gross profit	<b>14,008</b> (59.0)	<b>15,219</b> (59.9)	<b>1,211</b> (8.6)	<b>20,614</b> ( 73.8)	
( SG&A expenses )	<b>10,717</b> (45.1)	<b>11,809</b> (46.5)	<b>1,091</b> (10.2)	<b>16,306</b> ( 72.4)	
Operating income	<b>3,290</b> (13.9)	<b>3,409</b> (13.4)	<b>119</b> (3.6)	<b>4,308</b> (79.1)	
Ordinary income	<b>3,664</b> (15.4)	<b>3,692</b> (14.5)	<b>28</b> (0.8)	<b>4,572</b> (80.8)	
Net income	<b>2,796</b> (11.8)	<b>2,747</b> (10.8)	<b>- 48</b> ( -1.7)	<b>3,204</b> (85.7)	
Net income per share	157.29	154.97	-2.32	180.70	
Return on shareholders' equity	8.2%	7.4%	-0.8P	8.8%	
Forex					
USD	135.40	142.76	7.36	141.31	
EUR RMB	140.42 19.32	155.19 19.65	14.77 0.33	153.51 19.65	


<sup>\*</sup> Effect of forex fluctuations [Change from previous period]: Net sales +\pmu8802mn

<sup>\*</sup> Net income in the table refers to "net income attributable to owners of parent".

<sup>\*</sup> Full-year forecast for FY3/2024 is the revised plan announced on 10/24/2023.

# Operating income (YoY)





Net sales: +¥1,661mn (+7.0%)

Overseas sales growth and forex effects.

Operating income: +¥119mn (+3.6%)

OP increased due to sales growth OPM fell slightly due to higher SG&A, (particularly personnel expenses)


Cost of sales ratio: -0.9pt

Improved sales mix, yen depreciation.

SG&A ratio: +1.4pt


Higher SG&A ratio due to growth investment and bolstered marketing.

### Sales by product category (YoY)



- Resumption of aggressive sales promotions for chemical products as supply constraints eased.
- ✓ Special demand in the previous year for new CAD/CAM equipment in Japan fell back.
- ✓ Favorable inquiries for various new products including "EyeSpecial C-V" (digital dental cameras)

### Sales by region (YoY)




- North & Latin America on a recovery track since 3Q FY3/24. Sales recovered to flat YoY due to sales growth in "EyeSpecial C-V" (digital dental cameras) and chemical products, despite inventory adjustments in abrasive products.
- Exports from Japan to India, temporarily suspended from this fiscal year, resumed as regulatory approval filings were completed.

#### Operating income swing factors (YoY)

1-3Q FY3/23

Operating income



- ✓ Improvement in cost of sales ratio due to higher overseas sales ratio and better sales mix
- Ongoing upfront investments for growth, such as bolstering personnel and more R&D initiatives

1-3Q FY3/24 Operating


income

#### **Balance Sheet**

FY3/23

1-3Q FY3/24





#### Maintained strong financial position and high equity ratio (84.3%)

- Total assets (+1,997): More inventories, increase in investment securities amid rising market prices.
- : Higher valuation difference on securities and larger foreign currency Net assets (+3,197) translation adjustment.



# Consolidated Financial Results for 1-3Q FY March 2024

# Financial Forecasts for FY March 2024

TOPICS (Oct-Dec 2023)

#### Summary of Full-Year Forecasts



- Expect global dental market growth and strong demand, particularly in emerging countries
- Look for expansion in overseas business and improving sales mix
  - → Sales and income to reach a record high for the third consecutive year
- Aggressive investment in R&D, human resource development and facilities to enhance corporate value,
- Strengthening sales activities amid normalization of global economic activity
- Rising costs due to higher raw material and energy prices
  - → Continue to invest for future business growth
  - → Measures to address high costs include improving production and sales efficiency and revising product prices.
- Expect to clear backorders taken in the previous fiscal year, when production could not keep up with the surge in demand, in the current fiscal year.
  - → Establish a system to deal with future demand growth and address business risks.

# Comparison of key metrics

SHOFU

Units: ¥mn, %

	FY3/23 Actual (% of sales)		FY3/24 Forecast (% of sales)		Change From Previous Period (% change)		
Net sales	31,678	(100.0)	34,888	(100.0)	3,209	(10.1)	
(Domestic sales)	14,282	(45.1)	14,851	(42.6)	568	(4.0)	
(Overseas sales)	17,396	(54.9)	20,037	(57.4)	2,641	(15.2)	
Gross profit	18,699	(59.0)	20,614	(59.1)	1,914	(10.2)	
( SG&A expenses )	14,874	(47.0)	16,306	(46.7)	1,431	( 9.6)	
Operating income	3,824	(12.1)	4,308	(12.3)	483	(12.6)	
Ordinary income	4,238	(13.4)	4,572	(13.1)	333	(7.9)	
Net income	3,135	(9.9)	3,204	(9.2)	68	( 2.2)	
Net income per share	176.10		180.70		4.60		
Return on shareholders' equity	9.2%		8.8%		-0.4P		
Forex							
USD	134.95			141.31		6.36 12.27	
EUR RMB	141.24 19.38		153.51 19.65		0.27		

<sup>\*</sup>Effect of forex fluctuations (YoY): Net sales +¥940mn

<sup>\*</sup>Net income = net income attributable to owners of parent


# Segment forecasts (net sales & operating income)

SHOFU

Units: ¥mn

		FY3/23 Actual Amount (% of sales)	FY3/24 Forecast Amount (% of sales)	Change from Previous Period
Dental	Net sales	29,238	32,325	3,087
Business	Operating income	3,719	_	_
	(Operating income margin)	(12.7)		
Nail Care	Net sales	2,345	2,460	115
Business	Operating income	93	_	_
	(Operating income margin)	( 4.0)		
Other	Net sales	100	102	2
Businesses	Operating income	5	_	_
	(Operating income margin)	( 5.4)		
Total before	Net sales	31,684	34,888	3,204
consolidation	Operating income	3,818	<del>_</del>	<u> </u>
adjustment	(Operating income margin)	(12.1)		
Consolidated	Net sales	31,678	34,888	3,209
	Operating income	3,824	4,308	483
	(Operating income margin)	(12.1)	(12.3)	( 0.3)

### Sales by region (YoY)



- ✓ Domestic sales to remain solid amid stable demand
- ✓ Expect organic growth of ¥1,701mn (+9.8%) YoY for overseas sales (currency-neutral basis)
- ✓ Steady business growth in China and Europe (& Middle East) expected to contribute to overseas sales

### Forex impact



#### FY3/24 Forecast (Units: ¥mn)

	Forex rate		Consolidated earnings impact		Per yen of yen strength	
	FY3/23	FY3/24 Forecast	Sales	Operating income	Sales	Operating income
USD	134.95	141.31	255	132	-40	-17
EUR	141.24	153.51	517	221	-42	-17
RMB	19.38	19.65	64	10	-240	-150

- √ FY3/24 forex assumption used are actual rates from 2Q FY3/24 (USD: ¥6.36 depreciation YoY)
- ✓ Overseas sales ratio is increasing so yen depreciation has a positive impact on earnings



# Consolidated Financial Results for 1-3Q FY March 2024

# Financial Forecasts for FY March 2024

TOPICS (Oct-Dec 2023)

#### Dividend forecast revised



We revised our annual dividend forecast for FY3/2024 as follows (Feb 2, 2024)

	Dividends per share			Consolidated	DOE
	End of second quarter	Year-end	Annual	dividend payout ratio	DOE
Previous forecast (Released on May 10, 2023)		¥27.00	¥47.00	26.0%	
Current forecast		¥38.00	¥58.00	32.1%	
FY3/2024	¥20.00				
FY3/2023	¥15.00	¥42.00	¥57.00	32.4%	3.0%

(Notes) Year-end dividends for FY3/2023 included a commemorative dividend of ¥10.00 (100th anniversary of company's founding)

#### Annual dividend forecast raised by ¥11 vs previous forecast

Policy: Maintain stable dividends on an ongoing basis

Target: Consolidated dividend payout ratio of 30% or more

Dividend on equity (DOE) ratio of 1.7%

(May 10, 2023)

#### SHOFU BLOCK PEEK

Material for CAD/CAM crowns (V) now covered by health insurance



# SHOFU BLOCK PEEK can be used for all molars

Scope of crown restorations using CAD/CAM crowns covered by health insurance expanded (from Dec. 1, 2023)



SHOFU BLOCK

Only SHOFU BLOCK PEEK approved for health insurance for CAD/CAM crowns on all molars.

### **Features**

Reduced risk of failure **High toughness** 

Exceptional Biocompatibility

Gentle on natural teeth
Thin structure

Applicable

PEEK: Poly Ether Ether Ketone

A high-performance engineering thermoplastic that belongs to the family of polyketones




### Published SHOFU INC. Integrated Report 2023



#### SHOFU INC. Integrated Report 2023

https://pdf.irpocket.com/C7979/gX9u/T6Wc/MyGh.pdf







Forecasts in this document are based on information and data available at the time of release as well as on assumptions concerning uncertain factors that might affect the company's future business performance.

Depending on various factors, actual business performance could differ substantially from the forecasts contained in this document.

#### SHOFU INC.

11 Kamitakamatsu-cho, Fukuine, Higashiyama-ku, Kyoto 605-0983, Japan URL: http://www.shofu.co.jp E-mail: ir@shofu.co.jp

Contact: Corporate Planning Department